Bloomberg -- Amgen Inc. may deepen a push into cancer drugs beyond denosumab, the medicine approved last year to delay bone fractures in cancer patients, with three new oncology products in late-stage testing.
Bloomberg -- Amgen Inc. may deepen a push into cancer drugs beyond denosumab, the medicine approved last year to delay bone fractures in cancer patients, with three new oncology products in late-stage testing.
